95 results on '"Sontag MK"'
Search Results
2. A New Cystic Fibrosis Newborn Screening Algorithm: IRT/IRT1 upward arrow/DNA.
- Author
-
Sontag MK, Wright D, Beebe J, Accurso FJ, and Sagel SD
- Published
- 2009
- Full Text
- View/download PDF
3. Decreased total serum coenzyme-Q10 concentrations: a longitudinal study in children with cystic fibrosis.
- Author
-
Laguna TA, Sontag MK, Osberg I, Wagener JS, Accurso FJ, and Sokol RJ
- Abstract
OBJECTIVE: To assess total serum levels of coenzyme Q(10) (Co-Q(10)), an important antioxidant, in children with cystic fibrosis (CF) and to investigate an association between Co-Q(10) level and clinical outcome. STUDY DESIGN: Co-Q(10) levels were measured annually in a prospective cohort study of 381 children with CF. A total of 1092 serum levels of total Co-Q(10) were obtained by high-performance liquid chromatography and ultraviolet light detection. Associations of Co-Q(10) with demographic variables and clinical outcomes were investigated. RESULTS: Of the 381 initial total serum Co-Q(10) measurements, 188 were in the deficient range. Low Co-Q(10) was significantly more prevalent in patients with pancreatic insufficiency (PI) (55%) compared with patients with pancreatic sufficiency (PS) (3%); 22% of the patients with PI exhibited persistently low Co-Q(10) levels. Low Co-Q(10) levels were significantly associated with Pseudomonas aeruginosa colonization in patients with PI and CF under age 24 months, but not with subsequent lung function or hospitalization rates. Low Co-Q(10) levels were related to other markers of nutritional status, including total lipids, beta-carotene, and alpha-tocopherol. CONCLUSIONS: Persistently low total serum Co-Q(10) levels are common in children with CF and PI. A prospective study is indicated to determine whether Co-Q(10) supplementation in CF is beneficial. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
4. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis.
- Author
-
Rodman DM, Polis JM, Heltshe SL, Sontag MK, Chacon C, Rodman RV, Brayshaw SJ, Huitt GA, Iseman MD, Saavedra MT, Taussig LM, Wagener JS, Accurso FJ, and Nick JA
- Abstract
Although the median survival for patients with cystic fibrosis (CF) is 32.9 years, a small group of patients live much longer. We analyzed the genotype and phenotype of CF patients 40 years and older seen between 1992 and 2004 at the National Jewish Medical and Research Center (n = 55). These patients were divided into two groups according to age at diagnosis: an early diagnosis (ED) group, median age at diagnosis 2.0 years (range 0.1-15 years, n = 28), and a late diagnosis (LD) group, median age of diagnosis 48.8 years (range 24-72.8 years, n = 27). Consistent with the hypothesis that the CFTR genotype affects the age at diagnosis, CFTR Delta F508 homozygous individuals were more common in the ED group. Although patients in the ED group were predominantly male, the majority of LD patients were female. Patients with CF diagnosed late had a significantly lower prevalence of pancreatic insufficiency and CF-related diabetes, and better lung function. Fewer patients in the LD groups were infected with Pseudomonas aeruginosa, whereas a greater percentage had cultures positive for nontuberculous mycobacteria. This is the largest cohort of older patients with CF described to date, and our findings indicate that patients diagnosed as adults differ distinctly from survivors of long-term CF diagnosed as children. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
5. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report.
- Author
-
Comeau AM, Accurso FJ, White TB, Campbell PW 3rd, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Massie J, Farrell PM, O'Sullivan BP, and Cystic Fibrosis Foundation
- Published
- 2007
- Full Text
- View/download PDF
6. A Qualitative Study on Engaged Families' Experiences with Long-Term Follow-Up Care in the Colorado/Wyoming Newborn Screening System.
- Author
-
Quesada S, Barringer L, Sontag MK, and Kellar-Guenther Y
- Abstract
Understanding whether the long-term follow-up (LTFU) system is working for families is critical to measuring the success of newborn screening (NBS) and understanding why some families are lost to follow-up. Caregivers were recruited from six pediatric specialty care clinics. Data were gathered from caregivers via five focus groups and one individual interview ( n = 24). Caregiver participants represented a wide range of children's ages and conditions identified through NBS. While this is not the first study to gather caregivers' input on LTFU, it provides a wide breadth of perspectives (e.g., metabolic, endocrine, hemoglobinopathy, etc.). When asked about goals for their children, caregivers identified health-related goals (i.e., children able to care for themselves, not hindered by diagnosis) and non-health related goals (i.e., defining themselves outside of disease, participating in sports, making friends). In describing the LTFU care they want and need for their child and the key factors that influence access and engagement, caregivers identified three themes: communication and relationships with providers; care team roles and factors; and care access and utilization factors. The themes identified are not disjointed; they are intertwined and illustrate the lived experiences of a sample of families engaged in LTFU care., Competing Interests: At the time of data collection, Stacey Quesada, Yvonne Kellar-Guenther, and Marci Sontag were employed by CI International. These three authors are now employed by the Center for Public Health Innovation, a non-profit organization. Other authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
7. Defining the Minimal Long-Term Follow-Up Data Elements for Newborn Screening.
- Author
-
Kellar-Guenther Y, Barringer L, Raboin K, Nichols G, Chou KYF, Nguyen K, Burke AR, Fawbush S, Meyer JB, Dorsey M, Brower A, Chan K, Lietsch M, Taylor J, Caggana M, and Sontag MK
- Abstract
Newborn screening (NBS) is hailed as a public health success, but little is known about the long-term outcomes following a positive newborn screen. There has been difficulty gathering long-term follow-up (LTFU) data consistently, reliably, and with minimal effort. Six programs developed and tested a core set of minimal LTFU data elements. After an iterative data collection process and the development of a data collection tool, the group agreed on the minimal LTFU data elements. The denominator captured all infants with an NBS diagnosis, accounting for children who moved or died prior to the follow-up year. They also agreed on three LTFU outcomes: if the child was still alive, had contact with a specialist, and received appropriate care specific to their diagnosis within the year. The six programs representing NBS public health programs, clinical providers, and research programs provided data across multiple NBS disorders. In 2022, 83.8% (563/672) of the children identified by the LTFU programs were alive and living in the jurisdiction; of those, 92.0% (518/563) saw a specialist, and 87.7% (494/563) received appropriate care. The core LTFU data elements can be applied as a foundation to address the impact of early diagnosis by NBS within and across jurisdictions.
- Published
- 2024
- Full Text
- View/download PDF
8. Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability - Sickle Cell Data Collection Program, 11 States, 2016-2020.
- Author
-
Kayle M, Blewer AL, Pan W, Rothman JA, Polick CS, Rivenbark J, Fisher E, Reyes C, Strouse JJ, Weeks S, Desai JR, Snyder AB, Zhou M, Sutaria A, Valle J, Horiuchi SS, Sontag MK, Miller JI, Singh A, Dasgupta M, Janson IA, Galadanci N, Reeves SL, Latta K, Hurden I, Cromartie SJ, Plaxco AP, Mukhopadhyay A, Smeltzer MP, and Hulihan M
- Subjects
- Female, Child, Humans, Infant, Newborn, United States epidemiology, Prevalence, Cross-Sectional Studies, Social Vulnerability, Minority Groups, Ethnicity, Anemia, Sickle Cell epidemiology, Anemia, Sickle Cell diagnosis
- Abstract
Sickle cell disease (SCD) remains a public health priority in the United States because of its association with complex health needs, reduced life expectancy, lifelong disabilities, and high cost of care. A cross-sectional analysis was conducted to calculate the crude and race-specific birth prevalence for SCD using state newborn screening program records during 2016-2020 from 11 Sickle Cell Data Collection program states. The percentage distribution of birth mother residence within Social Vulnerability Index quartiles was derived. Among 3,305 newborns with confirmed SCD (including 57% with homozygous hemoglobin S or sickle β-null thalassemia across 11 states, 90% of whom were Black or African American [Black], and 4% of whom were Hispanic or Latino), the crude SCD birth prevalence was 4.83 per 10,000 (one in every 2,070) live births and 28.54 per 10,000 (one in every 350) non-Hispanic Black newborns. Approximately two thirds (67%) of mothers of newborns with SCD lived in counties with high or very high levels of social vulnerability; most mothers lived in counties with high or very high levels of vulnerability for racial and ethnic minority status (89%) and housing type and transportation (64%) themes. These findings can guide public health, health care systems, and community program planning and implementation that address social determinants of health for infants with SCD. Implementation of tailored interventions, including increasing access to transportation, improving housing, and advancing equity in high vulnerability areas, could facilitate care and improve health outcomes for children with SCD., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Sophia S. Horiuchi reports ownership of Natera stock and stock options and of Roche stock by her spouse. Mariam Kayle reports institutional support from Agios Medical Education Program and Novo Nordisk Independent Medical Education Activity to support the 11th Annual Sickle Cell Conference, September 8–9, 2023; receipt of consulting fees from Loyola University; receipt of honorarium for being an ad hoc reviewer from the National Institutes of Health (NIH), Center for Scientific Review, Social and Environmental Determinants of Health Study Section; and uncompensated membership in the American Society of Hematology Research Collaborative Data Hub Oversight Group, Sickle Cell Disease Subcommittee. Carri S. Polick reports support from the Veterans Administration and Duke University Clinical and Translational Science Institute. Ashima Singh reports institutional support from NIH, National Heart, Lung, and Blood Institute, the National Institute of Neurological Disorders and Stroke, and the Health Resources and Services Administration (HRSA) Sickle Cell Treatment Demonstration Program. John J. Strouse reports institutional support from the HRSA Southeast Region Coordinating Center Sickle Cell Treatment Demonstration Program and the North Carolina State Department of Health Sickle Cell Syndrome Program for the Duke Adult and Pediatric Sickle Cell Program; royalties from UpToDate for preparation of guidance on the use of hydroxyurea for sickle cell disease (SCD); consulting fees for GLG telephone consultation on SCD and Guidepoint telephone consultation on SCD; receipt of honoraria from the University of Rochester-Equity in Sickle Cell Disease Care; payment for medical legal expert testimony from Emory University in a case involving emergency department care of an adult with sickle beta thalassemia; travel support from the American Society of Hematology Sickle Cell Learning Community Meeting and Sickle Cell Disease Association of America Meeting to speak on behalf of the American Society of Hematology and travel support from the American Thrombosis Hemostasis Network Data Summit as an invited speaker on gene therapy for SCD: Design for Equity; payment for participation on a data safety monitoring board for disc medicines for phase 1 trial planning for bitopertin for SCD; and service as vice president of the Sickle Cell Adult Provider Network. No other potential conflicts of interest were disclosed.
- Published
- 2024
- Full Text
- View/download PDF
9. Late Diagnosis in the Era of Universal Newborn Screening Negatively Affects Short- and Long-Term Growth and Health Outcomes in Infants with Cystic Fibrosis.
- Author
-
Martiniano SL, Wu R, Farrell PM, Ren CL, Sontag MK, Elbert A, and McColley SA
- Subjects
- Infant, Newborn, Infant, Humans, Neonatal Screening, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Delayed Diagnosis, Mutation, Outcome Assessment, Health Care, Cystic Fibrosis diagnosis
- Abstract
Newborn screening for cystic fibrosis was fully implemented in the US by 2010, but delays in timeliness of evaluation for infants with positive newborn screening tests persist. Through evaluation of national patient registry data, we determined that late initiation of cystic fibrosis care is associated with poorer long-term nutritional outcomes., Competing Interests: Declaration of Competing Interest A.E. and R.W. are employees of the Cystic Fibrosis Foundation. Supported by the Cystic Fibrosis Foundation (MCCOLL19QI0). The other authors declare no conflicts of interest., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Tobacco smoke exposure, the lower airways microbiome and outcomes of ventilated children.
- Author
-
Leroue MK, Williamson KM, Curtin PC, Sontag MK, Wagner BD, Ambroggio L, Bixby M, Busgang SA, Murphy SE, Peterson LA, Vevang KR, Sipe CJ, Kirk Harris J, Reeder RW, Locandro C, Carpenter TC, Maddux AB, Simões EAF, Osborne CM, Robertson CE, Langelier C, Carcillo JA, Meert KL, Pollack MM, McQuillen PS, and Mourani PM
- Subjects
- Humans, Child, Critical Illness, Respiration, Artificial adverse effects, Smoke adverse effects, Nicotiana, Cotinine, Tobacco Smoke Pollution adverse effects, Respiratory Tract Infections, Microbiota
- Abstract
Background: Tobacco smoke exposure increases the risk and severity of lower respiratory tract infections in children, yet the mechanisms remain unclear. We hypothesized that tobacco smoke exposure would modify the lower airway microbiome., Methods: Secondary analysis of a multicenter cohort of 362 children between ages 31 days and 18 years mechanically ventilated for >72 h. Tracheal aspirates from 298 patients, collected within 24 h of intubation, were evaluated via 16 S ribosomal RNA sequencing. Smoke exposure was determined by creatinine corrected urine cotinine levels ≥30 µg/g., Results: Patients had a median age of 16 (IQR 568) months. The most common admission diagnosis was lower respiratory tract infection (53%). Seventy-four (20%) patients were smoke exposed and exhibited decreased richness and Shannon diversity. Smoke exposed children had higher relative abundances of Serratia spp., Moraxella spp., Haemophilus spp., and Staphylococcus aureus. Differences were most notable in patients with bacterial and viral respiratory infections. There were no differences in development of acute respiratory distress syndrome, days of mechanical ventilation, ventilator free days at 28 days, length of stay, or mortality., Conclusion: Among critically ill children requiring prolonged mechanical ventilation, tobacco smoke exposure is associated with decreased richness and Shannon diversity and change in microbial communities., Impact: Tobacco smoke exposure is associated with changes in the lower airways microbiome but is not associated with clinical outcomes among critically ill pediatric patients requiring prolonged mechanical ventilation. This study is among the first to evaluate the impact of tobacco smoke exposure on the lower airway microbiome in children. This research helps elucidate the relationship between tobacco smoke exposure and the lower airway microbiome and may provide a possible mechanism by which tobacco smoke exposure increases the risk for poor outcomes in children., (© 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
11. Evaluating the Discriminatory Ability of the Sickle Cell Data Collection Program's Administrative Claims Case Definition in Identifying Adults With Sickle Cell Disease: Validation Study.
- Author
-
Singh A, Sontag MK, Zhou M, Dasgupta M, Crume T, McLemore M, Galadanci N, Randall E, Steiner N, Brandow AM, Koch K, Field JJ, Hassell K, Snyder AB, and Kanter J
- Subjects
- United States epidemiology, Humans, Child, Adult, Medical Records, Registries, Alabama, Prevalence, Anemia, Sickle Cell diagnosis, Anemia, Sickle Cell epidemiology
- Abstract
Background: Sickle cell disease (SCD) was first recognized in 1910 and identified as a genetic condition in 1949. However, there is not a universal clinical registry that can be used currently to estimate its prevalence. The Sickle Cell Data Collection (SCDC) program, funded by the Centers for Disease Control and Prevention, funds state-level grantees to compile data within their states from various sources including administrative claims to identify individuals with SCD. The performance of the SCDC administrative claims case definition has been validated in a pediatric population with SCD, but it has not been tested in adults., Objective: The objective of our study is to evaluate the discriminatory ability of the SCDC administrative claims case definition to accurately identify adults with SCD using Medicaid insurance claims data., Methods: Our study used Medicaid claims data in combination with hospital-based medical record data from the Alabama, Georgia, and Wisconsin SCDC programs to identify individuals aged 18 years or older meeting the SCDC administrative claims case definition. In order to validate this definition, our study included only those individuals who were identified in both Medicaid's and the partnering clinical institution's records. We used clinical laboratory tests and diagnostic algorithms to determine the true SCD status of this subset of patients. Positive predictive values (PPV) are reported overall and by state under several scenarios., Results: There were 1219 individuals (354 from Alabama and 865 from Georgia) who were identified through a 5-year time period. The 5-year time period yielded a PPV of 88.4% (91% for data from Alabama and 87% for data from Georgia), when only using data with laboratory-confirmed (gold standard) cases as true positives. With a narrower time period (3-year period) and data from 3 states (Alabama, Georgia, and Wisconsin), a total of 1432 individuals from these states were included in our study. The overall 3-year PPV was 89.4% (92%, 93%, and 81% for data from Alabama, Georgia, and Wisconsin, respectively) when only considering laboratory-confirmed cases as true cases., Conclusions: Adults identified as having SCD from administrative claims data based on the SCDC case definition have a high probability of truly having the disease, especially if those hospitals have active SCD programs. Administrative claims are thus a valuable data source to identify adults with SCD in a state and understand their epidemiology and health care service usage., (©Ashima Singh, Marci K Sontag, Mei Zhou, Mahua Dasgupta, Tessa Crume, Morgan McLemore, Najibah Galadanci, Eldrida Randall, Nicole Steiner, Amanda M Brandow, Kathryn Koch, Joshua J Field, Kathryn Hassell, Angela B Snyder, Julie Kanter. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 28.06.2023.)
- Published
- 2023
- Full Text
- View/download PDF
12. Progress in expanding newborn screening in the United States.
- Author
-
Grosse SD, Cuthbert C, Gaffney M, Gaviglio A, Hinton CF, Kellar-Guenther Y, Kemper AR, McKasson S, Ojodu J, Riley C, Singh S, Sontag MK, and Shapira SK
- Subjects
- Infant, Newborn, United States, Humans, Neonatal Screening
- Published
- 2023
- Full Text
- View/download PDF
13. Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening.
- Author
-
McColley SA, Martiniano SL, Ren CL, Sontag MK, Rychlik K, Balmert L, Elbert A, Wu R, and Farrell PM
- Subjects
- Infant, Newborn, Infant, Humans, Neonatal Screening, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Retrospective Studies, Cohort Studies, Cystic Fibrosis diagnosis
- Abstract
Objective: We evaluated whether implementation of cystic fibrosis (CF) newborn screening (NBS) leads to equitable timeliness of initial evaluation. We compared age at first event (AFE, age at sweat test, encounter and/or care episode) between infants categorized as Black/African American, American Indian/ Native Alaskan, Asian, and/or Hispanic and/or other (Group 1) to White and not Hispanic infants (Group 2)., Methods: This retrospective cohort study from the Cystic Fibrosis Foundation Patient Registry (CFFPR) included infants born 2010-2018. Race and ethnicity categories followed US Census definitions. The primary outcome was AFE; the secondary outcome was weight for age (WFA) z-score averaged 12 to < 24 months. We compared distributions by Wilcoxon rank-sum test and proportions by Chi-square or Fisher's exact tests. A nested cohort study used a linear mixed effects model of variables that affect WFA, chosen a priori, to evaluate associations with 1-year WFA z-score., Results: Among 6354 infants, 21% were in Group 1. Group 1 median AFE was 31 days (IQR 19, 49) and Group 2 was 22 days (IQR 14,36) (p< .001). Median WFA z-score at 1-2 years was lower in Group 1. In 3017 infants with complete data on variables of interest, AFE, Black race, CFTR variant class I-III, prematurity and public insurance were associated with lower 1-year WFA z-score., Conclusions: Differences in AFE for infants with CF from historically marginalized groups may exacerbate long standing health disparities. We speculate that inequitable identification of CFTR gene variants and/or bias may influence timeliness of evaluation after an out-of-range NBS., Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest relevant to this article to disclose. Dr. Albert and Mr. Wu are employees of the Cystic Fibrosis Foundation., (Copyright © 2022. Published by Elsevier B.V.)
- Published
- 2023
- Full Text
- View/download PDF
14. Newborn Screening for Cystic Fibrosis: A Qualitative Study of Successes and Challenges from Universal Screening in the United States.
- Author
-
Sontag MK, Miller JI, McKasson S, Gaviglio A, Martiniano SL, West R, Vazquez M, Ren CL, Farrell PM, McColley SA, and Kellar-Guenther Y
- Abstract
Cystic fibrosis (CF) newborn screening (NBS) was universally adopted in 2009 in the United States. Variations in NBS practices between states may impact the timing of diagnosis and intervention. Quantitative metrics can provide insight into NBS programs (NBSP), but the nuances cannot be elucidated without additional feedback from programs. This study was designed to determine facilitators and barriers to timely diagnosis and intervention following NBS for CF. The median age at the first CF event for infants with CF within each state was used to define early and late states ( n = 15 per group); multiple CF centers were invited in states with more than two CF centers. Thirty states were eligible, and 61 NBSP and CF centers were invited to participate in structured interviews to determine facilitators and barriers. Once saturation of themes was reached, no other interviews were conducted. Forty-five interviews were conducted ( n = 16 early CF center, n = 12 late CF center, n = 11 early NBSP, and n = 6 late NBSP). Most interviewees reported good communication between CF centers and NBSP. Communication between primary care providers (PCPs) and families was identified as a challenge, leading to delays in referral and subsequent diagnosis. The misperception of low clinical risk in infants from racial and ethnic minority groups was a barrier to early diagnostic evaluation for all groups. NBSP and CF centers have strong relationships. Early diagnosis may be facilitated through more engagement with PCPs. Quality improvement initiatives should focus on continuing strong partnerships between CF centers and NBS programs, improving education, communication strategies, and partnerships with PCPs, and improving CF NBS timeliness and accuracy.
- Published
- 2022
- Full Text
- View/download PDF
15. Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study.
- Author
-
Martiniano SL, Elbert AA, Farrell PM, Ren CL, Sontag MK, Wu R, and McColley SA
- Subjects
- Child, Child, Preschool, Cohort Studies, Humans, Infant, Infant, Newborn, Neonatal Screening, Registries, Retrospective Studies, United States epidemiology, Cystic Fibrosis diagnosis, Cystic Fibrosis epidemiology
- Abstract
Introduction: Newborn screening (NBS) for cystic fibrosis (CF) was implemented in all US states and DC by 2010. This hypothesis-generating study was designed to form the basis of additional analyses and to plan quality improvement initiatives. The aims were to describe the outcomes of infants with CF born during the first 9 years of universal NBS., Methods: We included participants in the CF Foundation Patient Registry born 2010-2018 with age of recorded CF diagnosis 0-365 days old. We compared the age of center-reported diagnosis, age at first CF event (defined as earliest sweat test, clinic visit, or hospitalization), demographics, and outcomes between three cohorts born between 2010-2012, 2013-2015, and 2016-2018., Results: In 6354 infants, the median age at first CF event decreased from the first to the third cohort. Weight-for-age (WFA) was < 10th percentile in about 40% of infants at the first CF Center visit. Median WFA z-score at 1-2 years was more than 0 but height-for-age (HFA) z-score was less than 0 through age 5-6 years. The second cohort had a higher HFA z-score than the first cohort at age 5-6 years. Pseudomonas aeruginosa infection was less common in later cohorts. About 1/3 of infants were hospitalized in the first year of life with no changes over time., Conclusion: Over 9 years of CF NBS, median age at first CF event decreased. CF NBS had positive health impacts, but early life nutritional deficits and a high rate of infant hospitalizations persist., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
16. Improving outcomes for Colorado's IRT-IRT-DNA cystic fibrosis newborn screening algorithm by implementing floating cutoffs.
- Author
-
Martiniano SL, Croak K, Bonn G, Sontag MK, and Sagel SD
- Subjects
- Data Interpretation, Statistical, Genetic Testing methods, Genetic Testing statistics & numerical data, Humans, Infant, Newborn, Mutation, Neonatal Screening standards, Retrospective Studies, Sensitivity and Specificity, Trypsinogen analysis, Algorithms, Cystic Fibrosis diagnosis, Cystic Fibrosis genetics, Genetic Testing standards, Neonatal Screening methods
- Abstract
The Colorado Newborn Screening Program (CO-NBS) screens for cystic fibrosis (CF) by measuring immunoreactive trypsinogen (IRT) from two screens coupled with DNA analysis (IRT/IRT/DNA). The Colorado CF Care Center identified 8 missed CF cases among 358,187 infants screened by the CO-NSP since 2016. Retrospective analysis of CO-NSP IRT data shows that a 96th percentile floating IRT cutoff with a 50 ng/mL fixed cutoff on the first screen, and second screen 50 ng/mL fixed cutoff would have identified 7 of the 8 missed cases. These efforts demonstrate the importance of continuous quality improvement in order to increase sensitivity and reduce missed cases., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
17. Comment on Munck et al., Feb, 2021.
- Author
-
Sontag MK, Farrell PM, Kellar-Guenther Y, Martiniano SL, Miller JI, Ren CL, and McColley SA
- Subjects
- Humans, Cystic Fibrosis, Diabetes Mellitus, Type 2
- Abstract
Competing Interests: Declaration of competing interest The authors have no conflicts of interest that could inapproppriately influence this work.
- Published
- 2021
- Full Text
- View/download PDF
18. Modified PCR protocol to increase sensitivity for determination of bacterial community composition.
- Author
-
Williamson KM, Wagner BD, Robertson CE, Stevens MJ, Sontag MK, Mourani PM, and Harris JK
- Subjects
- Child, DNA, Bacterial genetics, Humans, RNA, Ribosomal, 16S genetics, Real-Time Polymerase Chain Reaction, Bacteria genetics, Microbiota genetics
- Abstract
Background: The objective of this project was to increase the sensitivity of sequence-based bacterial community determination without impacting community composition or interfering with cluster formation during sequencing. Two PCR protocols (standard and modified) were examined in airway samples where we observed a large range in bacterial load (3.1-6.2 log
10 16S rRNA gene copies/reaction). Tracheal aspirate (TA) samples (n = 99) were collected from sixteen children requiring mechanical ventilation at a single center. DNA was extracted, and total bacterial load (TBL) was assessed using qPCR. Amplification of 16S rRNA was attempted with both protocols in all samples., Results: PCR product was observed using both protocols in 52 samples and in 24 additional samples only with the modified protocol. TBL, diversity metrics, and prominent taxa were compared for samples in three groups based on success of the two protocols (successful with both, success with modified only, unsuccessful for both). TBL differed significantly across the three groups (p<0.001). Specifically, the modified protocol allowed amplification from samples with intermediate TBL. Shannon diversity was similar between the two protocols, and Morisita-Horn beta diversity index showed high agreement between the two protocols within samples (median value 0.9997, range 0.9947 to 1). We show that both protocols identify similar communities, and the technical variability of both protocols was very low. The use of limited PCR cycles was a key feature to limit impact of background by exclusion of 24% of samples with no evidence of bacterial DNA present in the sample., Conclusion: The modified amplification protocol represents a viable approach that increased sensitivity of bacterial community analysis, which is important for study of the human airway microbiome where bacterial load is highly variable. Video abstract.- Published
- 2021
- Full Text
- View/download PDF
19. Temporal airway microbiome changes related to ventilator-associated pneumonia in children.
- Author
-
Mourani PM, Sontag MK, Williamson KM, Harris JK, Reeder R, Locandro C, Carpenter TC, Maddux AB, Ziegler K, Simões EAF, Osborne CM, Ambroggio L, Leroue MK, Robertson CE, Langelier C, DeRisi JL, Kamm J, Hall MW, Zuppa AF, Carcillo J, Meert K, Sapru A, Pollack MM, McQuillen P, Notterman DA, Dean JM, and Wagner BD
- Subjects
- Child, Humans, Intensive Care Units, Prospective Studies, RNA, Ribosomal, 16S genetics, Microbiota, Pneumonia, Ventilator-Associated epidemiology
- Abstract
We sought to determine whether temporal changes in the lower airway microbiome are associated with ventilator-associated pneumonia (VAP) in children.Using a multicentre prospective study of children aged 31 days to 18 years requiring mechanical ventilation support for >72 h, daily tracheal aspirates were collected and analysed by sequencing of the 16S rRNA gene. VAP was assessed using 2008 Centers for Disease Control and Prevention paediatric criteria. The association between microbial factors and VAP was evaluated using joint longitudinal time-to-event modelling, matched case-control comparisons and unsupervised clustering.Out of 366 eligible subjects, 66 (15%) developed VAP at a median of 5 (interquartile range 3-5) days post intubation. At intubation, there was no difference in total bacterial load (TBL), but Shannon diversity and the relative abundance of Streptococcus , Lactobacillales and Prevotella were lower for VAP subjects versus non-VAP subjects. However, higher TBL on each sequential day was associated with a lower hazard (hazard ratio 0.39, 95% CI 0.23-0.64) for developing VAP, but sequential values of diversity were not associated with VAP. Similar findings were observed from the matched analysis and unsupervised clustering. The most common dominant VAP pathogens included Prevotella species (19%), Pseudomonas aeruginosa (14%) and Streptococcus mitis / pneumoniae (10%). Mycoplasma and Ureaplasma were also identified as dominant organisms in several subjects.In mechanically ventilated children, changes over time in microbial factors were marginally associated with VAP risk, although these changes were not suitable for predicting VAP in individual patients. These findings suggest that focusing exclusively on pathogen burden may not adequately inform VAP diagnosis., Competing Interests: Conflict of interest: P.M. Mourani reports grants from NIH NHLBI and NIH NICHD, during the conduct of the study. Conflict of interest: M.K. Sontag reports grants from NIH NHLBI, during the conduct of the study. Conflict of interest: K.M. Williamson has nothing to disclose. Conflict of interest: J.K. Harris has nothing to disclose. Conflict of interest: R. Reeder has nothing to disclose. Conflict of interest: C. Locandro has nothing to disclose. Conflict of interest: T.C. Carpenter reports grants from NIH NHLBI and NIH NICHD, during the conduct of the study. Conflict of interest: A.B. Maddux reports a grant from Parker B. Francis Foundation (Fellowship Award) and NIH/NICHD K23HD096018, outside the submitted work. Conflict of interest: K. Ziegler reports grants from NIH NHLBI during the conduct of the study. Conflict of interest: E.A.F. Simões reports grants from NIH NHLBI, during the conduct of the study. Conflict of interest: C.M. Osborne has nothing to disclose. Conflict of interest: L. Ambroggio has nothing to disclose. Conflict of interest: M.K. Leroue has nothing to disclose. Conflict of interest: C.E. Robertson has nothing to disclose. Conflict of interest: C. Langelier has nothing to disclose. Conflict of interest: J.L. DeRisi reports grants from NIH NHLBI, during the conduct of the study. Conflict of interest: J. Kamm has nothing to disclose. Conflict of interest: M.W. Hall reports grants from NIH NICHD, during the conduct of the study. Conflict of interest: A.F. Zuppa has nothing to disclose. Conflict of interest: J. Carcillo has nothing to disclose. Conflict of interest: K. Meert reports grants from NIH, during the conduct of the study. Conflict of interest: A. Sapru reports grants from NIH NICHD, during the conduct of the study. Conflict of interest: M.M. Pollack reports grants from NIH, during the conduct of the study. Conflict of interest: P. McQuillen reports grants from NIH NICHD, during the conduct of the study. Conflict of interest: D.A. Notterman has nothing to disclose. Conflict of interest: J.M. Dean reports grants from NIH, during the conduct of the study. Conflict of interest: B.D. Wagner reports grants from NIH NHLBI, during the conduct of the study., (Copyright ©ERS 2021.)
- Published
- 2021
- Full Text
- View/download PDF
20. Quantity not sufficient rates and delays in sweat testing in US infants with cystic fibrosis.
- Author
-
McColley SA, Elbert A, Wu R, Ren CL, Sontag MK, and LeGrys VA
- Subjects
- Gestational Age, Humans, Infant, Infant, Newborn, Neonatal Screening, Cystic Fibrosis diagnosis, Sweat
- Abstract
Background: Diagnostic sweat testing is required for infants with positive newborn-screening (NBS) tests for cystic fibrosis (CF). Infants have "quantity not sufficient" (QNS) sweat volumes more often than older children. A comprehensive study of QNS sweat volumes in infants has not previously been reported., Methods: We surveyed US CF Centers to obtain QNS rates in all infants who had sweat testing at under 14 days and under 3 months of age. We then calculated QNS rates reported to the Cystic Fibrosis Foundation Patient Registry (CFFPR) 2010-2018 in 10-day increments from 1 to 60 days of life. We compared QNS sweat test rates in preterm (<37-weeks gestational age) vs term infants. We assessed age at sweat test and proportion of infants who did not have a sweat test reported by 60 days of age., Results: Thirty-nine of 144 (27%) of CF Centers reported a mean QNS rate of 10.5% (range, 0-100) in infants 14-days-old or younger. CFFPR data showed the highest QNS rates in the youngest infants and in those born before 37 weeks of gestation. The median age at sweat testing decreased over time, but more than 22% of infants did not have a sweat test reported by 60 days., Conclusion: Higher QNS rates are seen in the youngest infants with CF, but more than 80% of infants younger than 2 weeks of age have adequate sweat volumes. Sweat testing should not be delayed in infants with a positive CF NBS test., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
21. Infants with Congenital Disorders Identified Through Newborn Screening - United States, 2015-2017.
- Author
-
Sontag MK, Yusuf C, Grosse SD, Edelman S, Miller JI, McKasson S, Kellar-Guenther Y, Gaffney M, Hinton CF, Cuthbert C, Singh S, Ojodu J, and Shapira SK
- Subjects
- Congenital Abnormalities epidemiology, Humans, Infant, Newborn, Prevalence, United States epidemiology, Congenital Abnormalities diagnosis, Neonatal Screening
- Abstract
Newborn screening (NBS) identifies infants at risk for congenital disorders for which early intervention has been shown to improve outcomes (1). State public health programs are encouraged to screen for disorders on the national Recommended Uniform Screening Panel (RUSP), which increased from 29 disorders in 2005 to 35 in 2018.* The RUSP includes hearing loss (HL) and critical congenital heart defects, which can be detected through point-of-care screening, and 33 disorders detected through laboratory screening of dried blood spot (DBS) specimens. Numbers of cases for 33 disorders on the RUSP (32 DBS disorders and HL) reported by 50 U.S. state programs were tabulated. The three subtypes of sickle cell disease (SCD) listed as separate disorders on the RUSP (S,S disease; S,beta-thalassemia; and S,C disease) were combined for the current analysis, and the frequencies of the resulting disorders were calculated relative to annual births. During 2015-2017, the overall prevalence was 34.0 per 10,000 live births. Applying that frequency to 3,791,712 live births in 2018,
† approximately 12,900 infants are expected to be identified each year with one of the disorders included in the study. The most prevalent disorder is HL (16.5 per 10,000), and the most prevalent DBS disorders are primary congenital hypothyroidism (CH) (6.0 per 10,000), SCD (4.9 per 10,000), and cystic fibrosis (CF) (1.8 per 10,000). Notable changes in prevalence for each of these disorders have occurred since the previous estimates based on 2006 births (2). The number of infants identified at a national level highlights the effect that NBS programs are having on infant health through early detection, intervention, and potential improved health, regardless of geographic, racial/ethnic, or socioeconomic differences., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Sari Edelman, Cynthia F. Hinton, Yvonne Kellar-Guenther, Sarah McKasson, Joshua I. Miller, Jelili Ojodu, Marci K. Sontag, Sikha Singh, and Careema Yusuf report grants from Health Resources and Services Administration during the conduct of the study. No other potential conflicts of interest were disclosed.- Published
- 2020
- Full Text
- View/download PDF
22. Implementing Statewide Newborn Screening for New Disorders: U.S. Program Experiences.
- Author
-
Kellar-Guenther Y, McKasson S, Hale K, Singh S, Sontag MK, and Ojodu J
- Abstract
Data were collected from 39 newborn screening (NBS) programs to provide insight into the time and factors required for implementing statewide screening for Pompe, Mucopolysaccharidosis type I (MPS I), adrenoleukodystrophy (ALD), and Spinal Muscular Atrophy (SMA). Newborn screening program readiness to screen statewide for a condition was assessed using four phases: (1) approval to screen; (2) laboratory, follow-up, and information technology capabilities; (3) education; and (4) implementation of statewide newborn screening. Seventeen states (43.6%) reached statewide implementation for at least one new disorder. Those states reported that it took 28 months to implement statewide screening for Pompe and MPS I, 30.5 months for ALD, and 20 months for SMA. Using survival curve analysis to account for states still in progress, the estimated median time to statewide screening increased to 75 months for Pompe and 66 months for MPS I. When looking at how long each readiness component took to complete, laboratory readiness was one of the lengthier processes, taking about 39 months. Collaboration with other NBS programs and hiring were the most frequently mentioned facilitators to implementing newborn screening. Staffing or inability to hire both laboratory and follow-up staff was the most frequently mentioned barrier., Competing Interests: Conflicts of InterestThe authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results., (© 2020 by the authors.)
- Published
- 2020
- Full Text
- View/download PDF
23. Newborn screening timeliness quality improvement initiative: Impact of national recommendations and data repository.
- Author
-
Sontag MK, Miller JI, McKasson S, Sheller R, Edelman S, Yusuf C, Singh S, Sarkar D, Bocchini J, Scott J, Ojodu J, and Kellar-Guenther Y
- Subjects
- Advisory Committees standards, Child, Humans, Infant, Newborn, Laboratories standards, Neonatal Screening standards, Quality Improvement standards
- Abstract
Background: Newborn screening (NBS) aims to achieve early identification and treatment of affected infants prior to onset of symptoms. The timely completion of each step (i.e., specimen collection, transport, testing, result reporting), is critical for early diagnosis. Goals developed by the Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) for NBS timeliness were adopted (time-critical results reported by five days of life, and non-time-critical results reported by day seven), and implemented into a multi-year quality improvement initiative (NewSTEPS 360) aimed to decrease the time to result reporting and intervention., Methods: The NBS system from specimen collection through reporting of results was assessed (bloodspot specimen collection, specimen shipping, sample testing, and result reporting). Annual data from 25 participating NBS programs were analyzed; the medians (and interquartile range, IQR) of state-specific percent of specimens that met the goal are presented., Results: The percent of specimens collected before 48 hours of life increased from 95% (88-97%) in 2016 to 97% (IQR 92-98%) in 2018 for the 25 states, with 20 (80%) of programs collecting more than 90% of the specimens within 48 hours of birth. Approximately 41% (IQR 29-57%) of specimens were transported within one day of collection. Time-critical result reporting in the first five days of life improved from 49% (IQR 26-74%) in 2016 to 64% (42%-71%) in 2018, and for non-time critical results from 64% (IQR 58%-78%) in 2016 to 81% (IQR 68-91%) in 2018. Laboratories open seven days a week in 2018 reported 95% of time-critical results within five days, compared to those open six days (62%), and five days (45%)., Conclusion: NBS programs that participated in NewSTEPs 360 made great strides in improving timeliness; however, ongoing quality improvement efforts are needed in order to ensure all infants receive a timely diagnosis., Competing Interests: The authors have read the journal's policy and have the following competing interests: MKS, JIM, and YKG are paid employees of CI International. The Cystic Fibrosis Foundation provided support for this study under Grant Number SONTAG16Q10 [MKS]. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products to declare.
- Published
- 2020
- Full Text
- View/download PDF
24. Development of National Newborn Screening Quality Indicators in the United States.
- Author
-
Yusuf C, Sontag MK, Miller J, Kellar-Guenther Y, McKasson S, Shone S, Singh S, and Ojodu J
- Abstract
Newborn screening is a public health program facilitated by state public health departments with the goal of improving the health of affected newborns throughout the country. Experts in the newborn screening community established a panel of eight quality indicators (QIs) to track quality practices within and across the United States newborn screening system. The indicators were developed following iterative refinement, consensus building, and evaluation. The Newborn Screening Technical assistance and Evaluation Program (NewSTEPs) implemented a national data repository in 2013 that captures the quality improvement metrics from each state. The QIs span the newborn screening process from collection of a dried blood spot through medical intervention for a screened condition. These data are collected and analyzed to support data-driven outcome assessments and tracking performance to improve the quality of the newborn screening system., Competing Interests: Conflicts of InterestThe authors declare no conflict of interest., (© 2019 by the authors.)
- Published
- 2019
- Full Text
- View/download PDF
25. Application of the New Centers for Disease Control and Prevention Surveillance Criteria for Ventilator-Associated Events to a Cohort of PICU Patients Identifies Different Patients Compared With the Previous Definition and Physician Diagnosis.
- Author
-
Ziegler KM, Haywood JD, Sontag MK, and Mourani PM
- Subjects
- Adolescent, Child, Child, Preschool, Humans, Infant, Intubation, Intratracheal, Prospective Studies, Respiration, Artificial, Socioeconomic Factors, Tertiary Care Centers, United States, Centers for Disease Control and Prevention, U.S. standards, Intensive Care Units, Pediatric standards, Pneumonia, Ventilator-Associated diagnosis, Pneumonia, Ventilator-Associated epidemiology
- Abstract
Objectives: We sought to compare the performance of the 2008 Centers for Disease Control and Prevention Pediatric criteria for ventilator-associated pneumonia, the 2013 Adult Ventilator-Associated Condition criteria, the new Draft Pediatric Ventilator-Associated Condition criteria, and physician-diagnosed ventilator-associated pneumonia in a cohort of PICU patients., Design: Secondary analysis of a previously conducted prospective observational study., Setting: PICU within a tertiary care children's hospital between April 1, 2010, and April 1, 2011., Patients: Patients between 31 days and 18 years old, mechanically ventilated via endotracheal tube for more than 72 hours and no limitations of care., Interventions: None., Measurements and Main Results: Ventilator-associated pneumonia criteria applied in real time and ventilator-associated condition criteria applied retrospectively. Outcomes assessed between cases and noncases within criteria. Of the 133 eligible participants, 24 (18%) had ventilator-associated pneumonia by 2008 Pediatric criteria and 27 (20%) by physician diagnosis. Sixteen (12%) and 10 (8%) had ventilator-associated condition by 2013 Adult and Draft Pediatric criteria, respectively. We found significant overlap between cases identified with 2008 Pediatric criteria and physician diagnosis (p = 0.549), but comparisons between the other definitions revealed that the newer criteria identify different patients than previous Centers for Disease Control and Prevention ventilator-associated pneumonia criteria and physician diagnosis (p < 0.01). Although 20 participants were diagnosed with ventilator-associated pneumonia by 2008 Pediatric criteria and physician diagnosis, only three participants were identified by all four criteria. Three subjects uniquely identified by the Draft Pediatric criteria were noninfectious in etiology. Cases identified by all criteria except Draft Pediatric had higher ratios of actual ICU length of stay to Pediatric Risk of Mortality III-adjusted expected length of stay compared with noncases., Conclusions: The Draft Pediatric criteria identify fewer and different patients than previous ventilator-associated pneumonia criteria or physician diagnosis, potentially missing patients with preventable harms, but also identified patients with potentially preventable noninfectious respiratory deteriorations. Further investigations are required to maximize the identification of patients with preventable harms from mechanical ventilation.
- Published
- 2019
- Full Text
- View/download PDF
26. Prenatal complications are associated with the postnatal airway host response and microbiota in intubated preterm infants.
- Author
-
Wagner BD, Sontag MK, Harris JK, Miller JI, Morrow L, Robertson CE, Stephens MJ, Poindexter BB, Abman SH, and Mourani PM
- Subjects
- Chorioamnionitis diagnosis, Chorioamnionitis microbiology, Female, Fetal Membranes, Premature Rupture diagnosis, Fetal Membranes, Premature Rupture microbiology, Gestational Age, Humans, Infant, Extremely Premature, Infant, Newborn, Infant, Very Low Birth Weight, Longitudinal Studies, Male, Pre-Eclampsia diagnosis, Pre-Eclampsia microbiology, Pregnancy, Prospective Studies, RNA, Ribosomal, 16S, Real-Time Polymerase Chain Reaction, Risk Factors, Staphylococcus genetics, Intubation, Intratracheal adverse effects, Lung microbiology, Microbiota, Premature Birth microbiology, Trachea microbiology
- Abstract
Purpose: To prospectively examine the relationship between prenatal events, postnatal airway host response and microbiota, and clinical outcomes., Materials and Methods: Tracheal aspirates collected at seven days of age from 71 mechanically ventilated infants (median gestational age (GA), 25 weeks [range 23-28]) were simultaneously processed for a 12-plex protein assay and bacterial identification by 16S rRNA sequencing. Phenotypes were determined by unsupervised clustering of the protein analytes. Subject characteristics, microbial communities and clinical factors and outcomes were compared across the phenotype groups., Results: Three clusters were identified: 1 (high protein levels), 2 (high proinflammatory proteins and low anti-inflammatory proteins), and 3 (low protein levels), respectively. Antenatal hemorrhage was most common in cluster 1, while chorioamnionitis characterized cluster 2 and preeclampsia was most prevalent in cluster 3, which was characterized by a predominance of Staphylococcus and relative absence of Ureaplasma. There were higher rates of adverse clinical outcomes in cluster 1., Conclusions: Airway protein profiles in seven days old mechanically ventilated preterm infants are associated with important antenatal events and unique airway microbial communities. These relationships may reveal new mechanisms by which antenatal events impact the course and outcomes of preterm infants.
- Published
- 2019
- Full Text
- View/download PDF
27. Analyzing Patterns in NewSTEPs Site Review Recommendations: Practical Applications for Newborn Screening Programs.
- Author
-
Kellar-Guenther Y, Sontag MK, Linder E, Singh S, Sheller R, and Ojodu J
- Abstract
The Newborn Screening Technical assistance and Evaluation Program (NewSTEPs) conducts non-regulatory site reviews of state newborn screening programs in the US with the goal of providing comprehensive reports and recommendations to support quality improvements within the system. A detailed coding and qualitative analysis of data extracted from reports of seven programs visited between 2012 and 2017, of thirteen pre-site visit surveys completed by state newborn screening programs, and of information from interviews conducted with three site review experts revealed four common themes that exist across states within the national newborn screening system. These themes include opportunities to implement improvements in: (1) communications inside and outside of the state newborn screening program, (2) education, (3) information technology, and (4) operations. The cross-cutting recommendations provided by NewSTEPs within the comprehensive site review reports may prove valuable for all state programs to consider and to incorporate as quality improvement measures in the absence of a full site review. The analysis of the site review process and recommendations identified important opportunities for improvement, many of which were previously unknown to be common across programs, and also provided affirmation of known challenges., Competing Interests: Conflicts of InterestThe authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results., (© 2019 by the authors.)
- Published
- 2019
- Full Text
- View/download PDF
28. Reply to Moossavi and Azad, "Quantifying and Interpreting the Association between Early-Life Gut Microbiota Composition and Childhood Obesity".
- Author
-
Stanislawski MA, Dabelea D, Wagner BD, Iszatt N, Dahl C, Sontag MK, Knight R, Lozupone CA, and Eggesbø M
- Subjects
- Child, Gastrointestinal Microbiome, Humans, Microbiota, Pediatric Obesity, Gastrointestinal Tract
- Published
- 2019
- Full Text
- View/download PDF
29. Clinical outcomes in U.S. infants with cystic fibrosis from 2001 to 2012.
- Author
-
Hoch H, Sontag MK, Scarbro S, Juarez-Colunga E, McLean C, Kempe A, and Sagel SD
- Subjects
- Child, Child, Preschool, Disease Progression, Female, Humans, Infant, Infant, Newborn, Male, Neonatal Screening methods, United States, Cystic Fibrosis diagnosis
- Abstract
Background: All 50 United States implemented newborn screening (NBS) for cystic fibrosis (CF) by 2010. The purpose of this study was to evaluate trends over the decade when NBS became universal to determine current rates of malnutrition, stunting, and infection rates in U.S. infants with CF., Methods: Annual data were obtained on infants with CF up to 24 months of age diagnosed between 2001 and 2010 in the CF Foundation Patient Registry (CFFPR), in both the years of and after diagnosis, including method of diagnosis, demographics, and growth parameters and microbiology., Results: Data were obtained on 8178 infants diagnosed with CF. The percentage of infants diagnosed by NBS increased from 15% in 2001-83% in 2012 (P < 0.001). Mean weight, length, and weight-for-length z-scores in the year of diagnosis increased from 2001 to 2012 (Wt z-score 2001: -1.32 (SD 1.41), 2012: -0.72 (SD 1.12); Ht z-score 2001: -1.32 (SD 1.57), 2012 -0.60 (SD 1.21); Wt/Ht Z score 2001: -0.54 (SD 1.18), 2012: 0.06 (SD 1.05); P < 0.001 for each). The proportion of infants on pancreatic enzymes decreased from 94% in 2001-83% in 2012 (P < 0.0001). Pseudomonas aeruginosa culture positivity in the diagnosis year decreased significantly (27% in 2001, 15% in 2012, P < 0.001)., Conclusions: Nationwide implementation of CF NBS is temporally associated with significant improvements in growth outcomes and reductions in P. aeruginosa infections. Current rates of malnutrition, stunting, and airway infection present a target for early intervention and quality improvement efforts., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
30. Pulse Oximetry Values in Newborns with Critical Congenital Heart Disease upon ICU Admission at Altitude.
- Author
-
Kim JS, Ariefdjohan MW, Sontag MK, and Rausch CM
- Abstract
Pulse oximetry screening for critical congenital heart disease (CCHD) has been recommended by the American Academy of Pediatrics (AAP). The objectives of this study are to describe saturation data, and to evaluate the effectiveness of AAP-recommended pulse oximetry screening guidelines applied retrospectively to a cohort of newborns with known CCHD at moderate altitude (5557 feet, Aurora, Colorado). Data related to seven critical congenital heart disease diagnoses were extracted from electronic health records (pulse oximetry, prostaglandin administration, and oxygen supplementation). Descriptive epidemiologic data were calculated. 158 subjects were included in this analysis; the AAP pulse oximetry screening protocol was applied to 149 subjects. Mean pre-ductal and post-ductal pulse oximetry values of the infants known to have CCHD at 24 h of life were 87.1% ± 7.2 and 87.8% ± 6.3, respectively. Infants treated with prostaglandins and oxygen had lower oximetry readings. The screening algorithm would have identified 80.5% of infants with known CCHDs (120/149 subjects). Additionally, sequential pulse oximetry screening based on the AAP-recommended protocol was able to identify a true positive screen capture rate of 80.5% at moderate altitude., Competing Interests: Conflicts of InterestSontag has received grants from the National Institutes of Heart Lung and Blood Disorders, the Health Services and Resources Administration, and the Cystic Fibrosis Foundation. Kim, Ariefdjohan, and Rausch declare that they have no conflicts of interest., (© 2018 by the authors.)
- Published
- 2018
- Full Text
- View/download PDF
31. Gut Microbiota in the First 2 Years of Life and the Association with Body Mass Index at Age 12 in a Norwegian Birth Cohort.
- Author
-
Stanislawski MA, Dabelea D, Wagner BD, Iszatt N, Dahl C, Sontag MK, Knight R, Lozupone CA, and Eggesbø M
- Subjects
- Age Factors, Bacteria isolation & purification, Child, Child, Preschool, DNA, Bacterial genetics, Female, Gestational Weight Gain, High-Throughput Nucleotide Sequencing, Humans, Infant, Infant, Newborn, Male, Mothers, Norway, Prospective Studies, RNA, Ribosomal, 16S genetics, Risk Factors, Weight Gain, Bacteria classification, Body Mass Index, Gastrointestinal Microbiome, Pediatric Obesity, Phylogeny
- Abstract
Childhood obesity is a growing problem worldwide. Recent research suggests that the gut microbiota may play an important and potentially causal role in the development of obesity and may be one mechanism that explains the transgenerational transmission of obesity risk. Here we examine the early-life gut microbiota at days 4, 10, 30, 120, 365, and 730 and the association with body mass index (BMI) z-scores at age 12 in a Norwegian prospective cohort ( n = 165), and evaluate how these BMI-associated taxa relate to maternal overweight/obesity (Ow/Ob) and excessive gestational weight gain (GWG). We performed 16S rRNA gene sequencing on the gut microbiota samples. Taxonomic phylogeny at days 10 and 730 was significantly associated with childhood BMI, and the gut microbiota taxa at two years of age explained over 50% of the variation in childhood BMI in this cohort. The subset of the early-life taxa within the gut microbiota that best predicted later childhood BMI showed substantial overlap with the maternal taxa most strongly associated with maternal Ow/Ob and excessive GWG. Our results show an association between the infant gut microbiota and later BMI, and they offer preliminary evidence that the infant gut microbiota, particularly at 2 years of age, may have potential to help identify children at risk for obesity. IMPORTANCE Understanding the role of the early-life gut microbiota in obesity is important because there may be opportunities for preventive strategies. We examined the relationships between infant gut microbiota at six times during the first two years of life and BMI at age 12 in a birth cohort of 165 children and their mothers. We found that the gut microbiota from early life to two years shows an increasingly strong association with childhood BMI. This study provides preliminary evidence that the gut microbiome at 2 years of age may offer useful information to help to identify youth who are at risk for obesity, which could facilitate more-targeted early prevention efforts., (Copyright © 2018 Stanislawski et al.)
- Published
- 2018
- Full Text
- View/download PDF
32. Gut microbiota in adolescents and the association with fatty liver: the EPOCH study.
- Author
-
Stanislawski MA, Lozupone CA, Wagner BD, Eggesbø M, Sontag MK, Nusbacher NM, Martinez M, and Dabelea D
- Subjects
- Adolescent, Body Mass Index, Child, Comorbidity, Diet, Feces, Female, Humans, Insulin Resistance, Magnetic Resonance Imaging, Male, Obesity, Prospective Studies, RNA, Ribosomal, 16S genetics, Surveys and Questionnaires, Young Adult, Gastrointestinal Microbiome, Liver diagnostic imaging, Non-alcoholic Fatty Liver Disease diagnosis, Non-alcoholic Fatty Liver Disease microbiology
- Abstract
Background: Recent evidence supports that the gut microbiota may be involved in the pathophysiology of non-alcoholic fatty liver disease (NAFLD), and may also offer avenues for treatment or prevention., Methods: We investigated the associations among gut microbiota, diet, and hepatic fat fraction (HFF) in 107 adolescents. Magnetic resonance imaging (MRI) was used to assess HFF, and 16S rRNA gene sequencing was performed on collected fecal samples. Dietary intake was assessed using Food Frequency Questionnaires. We examined the association between gut microbiota alpha diversity and HFF, and assessed the predictive accuracy for HFF of (1) taxonomic composition, (2) dietary intake, (3) demographic and comorbid conditions, and (4) the combination of these., Results: Lower alpha diversity was associated with higher HFF (β=-0.19, 95% confidence interval (CI) -0.36, -0.02). The selected taxa explained 17.7% (95% CI: 16.0-19.4%) of the variation in HFF. The combination of two of these taxa, Bilophila and Paraprevotella, with dietary intake of monounsaturated fatty acids and BMI z-scores explained 32.0% (95% CI: 30.3-33.6%) of the variation in HFF., Conclusion: The gut microbiota is associated with HFF in adolescents and may be useful to help identify youth who would be amenable to gut microbiota-based interventions.
- Published
- 2018
- Full Text
- View/download PDF
33. Case Definitions for Conditions Identified by Newborn Screening Public Health Surveillance.
- Author
-
Sontag MK, Sarkar D, Comeau AM, Hassell K, Botto LD, Parad R, Rose SR, Wintergerst KA, Smith-Whitley K, Singh S, Yusuf C, Ojodu J, Copeland S, and Hinton CF
- Abstract
Newborn screening (NBS) identifies infants with rare conditions to prevent death or the onset of irreversible morbidities. Conditions on the Health and Human Services Secretary's Recommended Uniform Screening Panel have been adopted by most state NBS programs, providing a consistent approach for identification of affected newborns across the United States. Screen-positive newborns are identified and referred for confirmatory diagnosis and follow-up. The designation of a clinically significant phenotype precursor to a clinical diagnosis may vary between clinical specialists, resulting in diagnostic variation. Determination of disease burden and birth prevalence of the screened conditions by public health tracking is made challenging by these variations. This report describes the development of a core group of new case definitions, along with implications, plans for their use, and links to the definitions that were developed by panels of clinical experts. These definitions have been developed through an iterative process and are piloted in NBS programs. Consensus public health surveillance case definitions for newborn screened disorders will allow for consistent categorization and tracking of short- and long-term follow-up of identified newborns at the local, regional, and national levels., Competing Interests: Conflicts of Interest: The authors declare no conflict of interest.
- Published
- 2018
- Full Text
- View/download PDF
34. NewSTEPs: The Establishment of a National Newborn Screening Technical Assistance Resource Center.
- Author
-
Ojodu J, Singh S, Kellar-Guenther Y, Yusuf C, Jones E, Wood T, Baker M, and Sontag MK
- Abstract
As newborn screening (NBS) programs in the US implement expanded screening panels, utilize emerging technologies and identify areas for improvement, the need to establish and maintain a community engagement based national technical assistance center becomes apparent. The Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)-a program of the Association of Public Health Laboratories (APHL) in partnership with the Colorado School of Public Health (ColoradoSPH), offers expertise in newborn screening program development, member connection, data analysis, and program evaluation. NewSTEPs provides a secure online data repository designed to collect comprehensive data on newborn screening programs in three strata: state profiles (description of each state program including program hours, fees, and disorders screened), quality indicators (metrics of program performance encompassing screening accuracy and timeliness) and NBS public health surveillance case definitions. NewSTEPs was created in 2012 under a cooperative agreement with the United States Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB). Successful activities of NewSTEPs have resulted in the establishment of a technical assistance resource center and the organization of a network of newborn screening experts. In addition, NewSTEPs coordinates efforts with other federally funded programs in order to maximize resources and to ensure a unified approach to data collection and information sharing., Competing Interests: Conflicts of InterestThe authors declare they have no conflicts or competing interests., (© 2017 by the authors.)
- Published
- 2017
- Full Text
- View/download PDF
35. Molecular analysis of endotracheal tube biofilms and tracheal aspirates in the pediatric intensive care unit.
- Author
-
Leroue MK, Harris JK, Burgess KM, Stevens MJ, Miller JI, Sontag MK, Sierra YL, Wagner BD, and Mourani PM
- Abstract
Background: Ventilator-associated pneumonia (VAP) is a known complication of mechanically ventilated children in the pediatric intensive care unit (PICU). Endotracheal tube (ETT) biofilms are often implicated in the development of VAP by providing a conduit for pathogens to the lower respiratory tract., Methods: A prospective cohort study from April 2010-March 2011 of children 4 weeks to 18 years of age ventilated for greater than 72 hours to determine the microbiota of ETT biofilms and tracheal aspirates., Results: Thirty-three patients were included with a mean age of 6.1 years (SD ± 5.1 years) and average length of intubation of 8.8 days (SD ± 5.0 days). Bacterial communities from tracheal aspirates and the proximal and distal ends of ETTs were determined using 16S rRNA gene libraries. Statistical analysis utilized two-part statistics and the Wilcoxon signed rank sum test for comparison of bacterial communities. Sequencing revealed a predominance of oropharyngeal microbiota including Prevotella and Streptococcus spp. Pathogenic bacterial genera including Staphylococcus, Burkholderia, Moraxella, and Haemophilus were also represented. Bacterial load was greatest at the proximal aspect of the ETT. Duration of intubation did not significantly impact bacterial load. Morisita Horn analysis across sites showed similar communities in 24/33 (72%) of patients., Conclusions: ETT biofilms and tracheal aspirates of intubated patients in the PICU primarily consisted of oropharyngeal microbiota, but had a significant representation of potentially pathogenic genera. While the majority of patients had similar microbiota when comparing their ETT biofilms and tracheal aspirates, a subset of patients showed a divergence between communities that requires further investigation., Competing Interests: Competing interests: The authors have declared that no competing interests exist.
- Published
- 2017
- Full Text
- View/download PDF
36. Complete Genome Sequence of a Divergent Human Rhinovirus C Isolate from an Infant with Severe Community-Acquired Pneumonia in Colorado, USA.
- Author
-
Langelier C, White CV, Sontag MK, Mourani PM, and DeRisi JL
- Abstract
Here, we report the genome sequence of a divergent human rhinovirus C isolate identified from an infant with a severe community-acquired respiratory infection. RNA sequencing performed on an Illumina platform identified reads aligning to human rhinovirus species, which were de novo assembled to produce a coding-complete genome sequence., (Copyright © 2017 Langelier et al.)
- Published
- 2017
- Full Text
- View/download PDF
37. Ventilator-Associated Pneumonia in Critically Ill Children: A New Paradigm.
- Author
-
Mourani PM and Sontag MK
- Subjects
- Child, Critical Care methods, Critical Illness, Humans, Lung microbiology, Metagenomics, Microbiota, Proteomics, Risk Factors, Pneumonia, Ventilator-Associated diagnosis, Pneumonia, Ventilator-Associated etiology, Pneumonia, Ventilator-Associated therapy
- Abstract
Ventilator-associated pneumonia (VAP) is a serious complication of critical illness. Surveillance definitions have undergone revisions for more objective and consistent reporting. The 1 organism-1 disease paradigm for microbial involvement may not adequately apply to many cases of VAP, in which pathogens are introduced to a pre-existing and often complex microbial community that facilitates or hinders the potential pathogen, consequently determining whether progression to VAP occurs. As omics technology is applied to VAP, a paradigm is emerging incorporating simultaneous assessments of microbial populations and their activity, as well as the host response, to personalize prevention and treatment., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
38. Pre-pregnancy weight, gestational weight gain, and the gut microbiota of mothers and their infants.
- Author
-
Stanislawski MA, Dabelea D, Wagner BD, Sontag MK, Lozupone CA, and Eggesbø M
- Subjects
- Adult, Bacteria classification, Bacteria genetics, Bacteria isolation & purification, Bifidobacterium classification, Bifidobacterium genetics, Bifidobacterium isolation & purification, Body Mass Index, Child, Preschool, Female, Genes, rRNA, High-Throughput Nucleotide Sequencing, Humans, Infant, Infant, Newborn, Mothers, Overweight, RNA, Ribosomal, 16S genetics, Gastrointestinal Microbiome genetics, Obesity, Pregnancy, Weight Gain
- Abstract
Background: Recent evidence supports that the maternal gut microbiota impacts the initial infant gut microbiota. Since the gut microbiota may play a causal role in the development of obesity, it is important to understand how pre-pregnancy weight and gestational weight gain (GWG) impact the gut microbiota of mothers at the time of delivery and their infants in early life. In this study, we performed 16S rRNA gene sequencing on gut microbiota samples from 169 women 4 days after delivery and from the 844 samples of their infants at six timepoints during the first 2 years of life. We categorized the women (1) according to pre-pregnancy body mass index into overweight/obese (OW/OB, BMI ≥ 25) or non-overweight/obese (BMI < 25) and (2) into excessive and non-excessive GWG in the subset of mothers of full-term singleton infants (N = 116). We compared alpha diversity and taxonomic composition of the maternal and infant samples by exposure groups. We also compared taxonomic similarity between maternal and infant gut microbiota., Results: Maternal OW/OB was associated with lower maternal alpha diversity. Maternal pre-pregnancy OW/OB and excessive GWG were associated with taxonomic differences in the maternal gut microbiota, including taxa from the highly heritable family Christensenellaceae, the genera Lachnospira, Parabacteroides, Bifidobacterium, and Blautia. These maternal characteristics were not associated with overall differences in the infant gut microbiota over the first 2 years of life. However, the presence of specific OTUs in maternal gut microbiota at the time of delivery did significantly increase the odds of presence in the infant gut at age 4-10 days for many taxa, and these included some lean-associated taxa., Conclusions: Our results show differences in maternal gut microbiota composition at the time of delivery by pre-pregnancy weight and GWG, but these changes were only associated with limited compositional differences in the early life gut microbiota of their infants. Further work is needed to determine the degree to which these maternal microbiota differences at time of birth with OW/OB and GWG may affect the health of the infant over time and by what mechanism.
- Published
- 2017
- Full Text
- View/download PDF
39. CDC Grand Rounds: Newborn Screening for Hearing Loss and Critical Congenital Heart Disease.
- Author
-
Grosse SD, Riehle-Colarusso T, Gaffney M, Mason CA, Shapira SK, Sontag MK, Braun KVN, and Iskander J
- Subjects
- Centers for Disease Control and Prevention, U.S., Early Diagnosis, Humans, Infant, Newborn, Program Evaluation, United States, Hearing Loss diagnosis, Heart Defects, Congenital diagnosis, Neonatal Screening methods, Point-of-Care Systems
- Abstract
Newborn screening is a public health program that benefits 4 million U.S. infants every year by enabling early detection of serious conditions, thus affording the opportunity for timely intervention to optimize outcomes (1). States and other U.S. jurisdictions decide whether and how to regulate newborn screening practices. Most newborn screening is done through laboratory analyses of dried bloodspot specimens collected from newborns. Point-of-care newborn screening is typically performed before discharge from the birthing facility. The Recommended Uniform Screening Panel includes two point-of-care conditions for newborn screening: hearing loss and critical congenital heart disease (CCHD). The objectives of point-of-care screening for these two conditions are early identification and intervention to improve neurodevelopment, most notably language and related skills among infants with permanent hearing loss, and to prevent death or severe disability resulting from delayed diagnosis of CCHD. Universal screening for hearing loss using otoacoustic emissions or automated auditory brainstem response was endorsed by the Joint Committee on Infant Hearing in 2000 and 2007* and was incorporated in the first Recommended Uniform Screening Panel in 2005. Screening for CCHD using pulse oximetry was recommended by the Advisory Committee on Heritable Disorders in Newborns and Children in 2010 based on an evidence review
† and was added to the Recommended Uniform Screening Panel in 2011.§ .- Published
- 2017
- Full Text
- View/download PDF
40. Antenatal Determinants of Bronchopulmonary Dysplasia and Late Respiratory Disease in Preterm Infants.
- Author
-
Morrow LA, Wagner BD, Ingram DA, Poindexter BB, Schibler K, Cotten CM, Dagle J, Sontag MK, Mourani PM, and Abman SH
- Subjects
- Causality, Colorado epidemiology, Female, Follow-Up Studies, Humans, Hypertension epidemiology, Infant, Newborn, Longitudinal Studies, Male, Pregnancy, Prospective Studies, Risk Factors, Surveys and Questionnaires, Bronchopulmonary Dysplasia epidemiology, Infant, Premature, Mothers statistics & numerical data, Prenatal Exposure Delayed Effects epidemiology, Respiratory Distress Syndrome, Newborn epidemiology, Smoking epidemiology
- Abstract
Rationale: Mechanisms contributing to chronic lung disease after preterm birth are incompletely understood., Objectives: To identify antenatal risk factors associated with increased risk for bronchopulmonary dysplasia (BPD) and respiratory disease during early childhood after preterm birth, we performed a prospective, longitudinal study of 587 preterm infants with gestational age less than 34 weeks and birth weights between 500 and 1,250 g., Methods: Data collected included perinatal information and assessments during the neonatal intensive care unit admission and longitudinal follow-up by questionnaire until 2 years of age., Measurements and Main Results: After adjusting for covariates, we found that maternal smoking prior to preterm birth increased the odds of having an infant with BPD by twofold (P = 0.02). Maternal smoking was associated with prolonged mechanical ventilation and respiratory support during the neonatal intensive care unit admission. Preexisting hypertension was associated with a twofold (P = 0.04) increase in odds for BPD. Lower gestational age and birth weight z-scores were associated with BPD. Preterm infants who were exposed to maternal smoking had higher rates of late respiratory disease during childhood. Twenty-two percent of infants diagnosed with BPD and 34% of preterm infants without BPD had no clinical signs of late respiratory disease during early childhood., Conclusions: We conclude that maternal smoking and hypertension increase the odds for developing BPD after preterm birth, and that maternal smoking is strongly associated with increased odds for late respiratory morbidities during early childhood. These findings suggest that in addition to the BPD diagnosis at 36 weeks, other factors modulate late respiratory outcomes during childhood. We speculate that measures to reduce maternal smoking not only will lower the risk for preterm birth but also will improve late respiratory morbidities after preterm birth.
- Published
- 2017
- Full Text
- View/download PDF
41. Erratum to: Critical Congenital Heart Disease Newborn Screening Implementation: Lessons Learned.
- Author
-
McClain MR, Hokanson JS, Grazel R, Van Naarden Braun K, Garg LF, Morris MR, Moline K, Urquhart K, Nance A, Randall H, and Sontag MK
- Published
- 2017
- Full Text
- View/download PDF
42. Reliability of Echocardiographic Indicators of Pulmonary Vascular Disease in Preterm Infants at Risk for Bronchopulmonary Dysplasia.
- Author
-
Carlton EF, Sontag MK, Younoszai A, DiMaria MV, Miller JI, Poindexter BB, Abman SH, and Mourani PM
- Subjects
- Age Factors, Female, Humans, Infant, Newborn, Infant, Premature, Male, Observer Variation, Prospective Studies, Reproducibility of Results, Risk Factors, Bronchopulmonary Dysplasia diagnostic imaging, Bronchopulmonary Dysplasia etiology, Echocardiography, Vascular Diseases diagnostic imaging, Vascular Diseases etiology
- Abstract
Objectives: To determine the assessment and inter-rater reliability of echocardiographic evaluations of pulmonary vascular disease (PVD) in preterm infants at risk for bronchopulmonary dysplasia., Study Design: We prospectively studied echocardiograms from preterm infants (birthweights 500-1250 g) at 7 days of age and 36 weeks postmenstrual age (PMA). Echocardiograms were assessed by both a cardiologist on clinical service and a single research cardiologist. Interpretations were reviewed for inclusion of determinants of PVD and assessed for inter-rater reliability using the Prevalence Adjusted Bias Adjusted Kappa Score (PABAK)., Results: One hundred eighty and 188 matching research and clinical echocardiogram reports were available for the 7-day and 36-week PMA studies. At least one of the specific qualitative measures of PVD was missing from 54% of the clinical reports. PVD was diagnosed at 7 days in 31% and 20% of research and clinical interpretations, respectively (PABAK score of 0.54). At 36 weeks, PH was diagnosed in 15.6% and 17.8% of research and clinical interpretations, respectively (PABAK score of 0.80)., Conclusions: Although all qualitative variables of PVD are not consistently provided in echocardiogram reports, the inter-rater reliability of cardiologists evaluating measures of PVD revealed strong agreement, especially at 36 weeks PMA. We speculate that establishment of a protocol for echocardiographic evaluation may improve the identification of PVD in preterm infants., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
43. Critical Congenital Heart Disease Newborn Screening Implementation: Lessons Learned.
- Author
-
McClain MR, Hokanson JS, Grazel R, Van Naarden Braun K, Garg LF, Morris MR, Moline K, Urquhart K, Nance A, Randall H, and Sontag MK
- Subjects
- Female, Health Services Accessibility, Humans, Infant, Newborn, Practice Guidelines as Topic standards, Pregnancy, Qualitative Research, Quality Improvement, United States, Health Plan Implementation organization & administration, Heart Defects, Congenital diagnosis, Neonatal Screening methods, Neonatal Screening organization & administration
- Abstract
Introduction The purpose of this article is to present the collective experiences of six federally-funded critical congenital heart disease (CCHD) newborn screening implementation projects to assist federal and state policy makers and public health to implement CCHD screening. Methods A qualitative assessment and summary from six demonstration project grantees and other state representatives involved in the implementation of CCHD screening programs are presented in the following areas: legislation, provider and family education, screening algorithms and interpretation, data collection and quality improvement, telemedicine, home and rural births, and neonatal intensive care unit populations. Results The most common challenges to implementation include: lack of uniform legislative and statutory mandates for screening programs, lack of funding/resources, difficulty in screening algorithm interpretation, limited availability of pediatric echocardiography, and integrating data collection and reporting with existing newborn screening systems. Identified solutions include: programs should consider integrating third party insurers and other partners early in the legislative/statutory process; development of visual tools and language modification to assist in the interpretation of algorithms, training programs for adult sonographers to perform neonatal echocardiography, building upon existing newborn screening systems, and using automated data transfer mechanisms. Discussion Continued and expanded surveillance, research, prevention and education efforts are needed to inform screening programs, with an aim to reduce morbidity, mortality and other adverse consequences for individuals and families affected by CCHD.
- Published
- 2017
- Full Text
- View/download PDF
44. Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.
- Author
-
Pittman JE, Noah H, Calloway HE, Davis SD, Leigh MW, Drumm M, Sagel SD, Accurso FJ, Knowles MR, and Sontag MK
- Subjects
- Adolescent, Age Factors, Alleles, Case-Control Studies, Child, Child, Preschool, Cystic Fibrosis diagnosis, Cystic Fibrosis genetics, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Female, Humans, Infant, Male, Prognosis, Pseudomonas Infections diagnosis, Registries, Respiratory Function Tests, Cystic Fibrosis complications, Cystic Fibrosis physiopathology, Lung physiopathology, Pseudomonas Infections etiology, Pseudomonas Infections physiopathology, Pseudomonas aeruginosa
- Abstract
Objective: Pseudomonas aeruginosa has been suggested as a major determinant of poor pulmonary outcomes in cystic fibrosis (CF), although other factors play a role. Our objective was to investigate the association of early childhood Pseudomonas infection on differences in lung function in adolescence with CF., Methods: Two populations of subjects with CF were studied: from the Gene Modifier Study (GMS), 346 F508del homozygotes with severe vs. mild adolescent lung disease, and from the Colorado Newborn Screen Study (NBS) 172 subjects diagnosed with CF by newborn screening. Associations of Pseudomonas infection and lung function in early childhood with lung function in adolescence were investigated using multivariate linear regression analyses., Results: Among GMS subjects, those with severe adolescent lung disease had worse lung function in childhood (FEV1 25 percentage points lower) compared to subjects with mild adolescent lung disease, regardless of early childhood Pseudomonas status. Among NBS subjects, those with lowest adolescent lung function had significantly lower early childhood lung function and faster rate of decline in FEV1 than subjects with highest adolescent lung function; early Pseudomonas infection was not associated with rate of FEV1 decline. The strongest predictor of adolescent lung function was early childhood lung function. Subjects with a higher percentage of cultures positive for Pseudomonas before age 6 or a lower BMI at 2-4 years old also had lower adolescent lung function, though these associations were not as strong as with early childhood lung function., Conclusions: In separate analyses of two distinct populations of subjects with CF, we found a strong correlation between lower lung function in early childhood and adolescence, regardless of early childhood Pseudomonas status. Factors in addition to early Pseudomonas infection have a strong impact on lung function in early childhood in CF. Further exploration may identify novel underlying genetic or environmental factors that predispose children with CF to early loss of lung function.
- Published
- 2017
- Full Text
- View/download PDF
45. Airway Microbial Community Turnover Differs by BPD Severity in Ventilated Preterm Infants.
- Author
-
Wagner BD, Sontag MK, Harris JK, Miller JI, Morrow L, Robertson CE, Stephens M, Poindexter BB, Abman SH, and Mourani PM
- Subjects
- Birth Weight, Bronchopulmonary Dysplasia genetics, Bronchopulmonary Dysplasia pathology, Female, Gestational Age, Humans, Infant, Newborn, Infant, Premature, Intubation, Intratracheal adverse effects, Lung pathology, Male, Pregnancy, Premature Birth microbiology, Premature Birth pathology, Respiration, Artificial, Staphylococcus genetics, Staphylococcus isolation & purification, Staphylococcus pathogenicity, Trachea pathology, Bronchopulmonary Dysplasia microbiology, Lung microbiology, RNA, Ribosomal, 16S genetics, Trachea microbiology
- Abstract
Preterm birth exposes the developing lung to an environment with direct exposure to bacteria, often facilitated by endotracheal intubation. Despite evidence linking bacterial infections to the pathogenesis of bronchopulmonary dysplasia (BPD), systematic studies of airway microbiota are limited. The objective was to identify specific patterns of the early respiratory tract microbiome from tracheal aspirates of mechanically ventilated preterm infants that are associated with the development and severity of BPD. Infants with gestational age ≤34 weeks, and birth weight 500-1250g were prospectively enrolled. Mechanically ventilated infants had tracheal aspirate samples collected at enrollment, 7, 14, and 21 days of age. BPD was determined by modified NIH criteria with oxygen reduction tests; infants without BPD were excluded due to low numbers. Aspirates were processed for bacterial identification by 16S rRNA sequencing, and bacterial load by qPCR. Cross-sectional analysis was performed using 7 day samples and longitudinal analysis was performed from subjects with at least 2 aspirates. Microbiome analysis was performed on tracheal aspirates from 152 infants (51, 49, and 52 with mild, moderate, and severe BPD, respectively). Seventy-nine of the infants were included in the cross-sectional analysis and 94 in the longitudinal. Shannon Diversity, bacterial load, and relative abundance of individual taxa were not strongly associated with BPD status. Longitudinal analysis revealed that preterm infants who eventually developed severe BPD exhibited greater bacterial community turnover with age, acquired less Staphylococcus in the first days after birth, and had higher initial relative abundance of Ureaplasma. In conclusion, longitudinal changes in the airway microbial communities of mechanically ventilated preterm infants may be associated with BPD severity, whereas cross-sectional analysis of airway ecology at 7 days of age did not reveal an association with BPD severity. Further evaluation is necessary to determine whether the observed longitudinal changes are causal or in response to clinical management or other factors that lead to BPD., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2017
- Full Text
- View/download PDF
46. Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen.
- Author
-
Woodruff SA, Sontag MK, Accurso FJ, Sokol RJ, and Narkewicz MR
- Subjects
- Adolescent, Child, Preschool, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Female, Humans, Infant, Newborn, Liver Function Tests methods, Liver Function Tests statistics & numerical data, Male, Neonatal Screening methods, Prevalence, Prognosis, Statistics as Topic, United States epidemiology, Young Adult, Alanine Transaminase blood, Aspartate Aminotransferases blood, Cystic Fibrosis blood, Cystic Fibrosis complications, Cystic Fibrosis diagnosis, Cystic Fibrosis epidemiology, Liver Diseases diagnosis, Liver Diseases epidemiology, Liver Diseases etiology, gamma-Glutamyltransferase blood
- Abstract
Background: Prevalence and risks for elevated liver enzymes have not been studied systematically in children with CF identified by newborn screen., Methods: 298 CF children identified by newborn screen since 1982. AST, ALT and GGT tested at annual visits. Percent of children with 1 or ≥2 values of elevated AST, ALT and GGT determined. Relationship of liver enzymes to clinical factors or subsequent liver disease was analyzed RESULTS: At least one abnormal value for AST (63%), ALT (93%) and ALT ≥1.5× ULN (52%) occurred by 21years of age. Liver enzyme elevations were not correlated with CFTR mutation, meconium ileus or ethnicity. AST and GGT ≥1.5× ULN were associated with later advanced liver disease HR (CI) 6.53 (2.02-21.1) and 4.03 (1.15-13.45), respectively., Conclusions: Elevated liver enzymes are common during childhood in CF patients identified by newborn screen. Elevated AST and GGT may be markers for risk of advanced liver disease., (Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
47. Sweat Chloride: The Critical Biomarker for Cystic Fibrosis Trials.
- Author
-
Sontag MK
- Subjects
- Biomarkers, Chlorides, Cystic Fibrosis Transmembrane Conductance Regulator, Humans, Cystic Fibrosis, Sweat
- Published
- 2016
- Full Text
- View/download PDF
48. Cystic Fibrosis Diagnosis and Newborn Screening.
- Author
-
Rosenfeld M, Sontag MK, and Ren CL
- Subjects
- Adult, Child, Child, Preschool, Humans, Infant, Newborn, Mutation, Cystic Fibrosis diagnosis, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Neonatal Screening methods
- Abstract
The diagnosis of cystic fibrosis (CF) has evolved over the past decade as newborn screening has become universal in the United States and elsewhere. The heterogeneity of phenotypes associated with CF transmembrane conductance regulator (CFTR) dysfunction and mutations in the CFTR gene has become clearer, ranging from classic pancreatic-insufficient CF to manifestations in only 1 organ system to indeterminate diagnoses identified by newborn screening. The tools available for diagnosis have also expanded. This article reviews the newest diagnostic criteria for CF, newborn screening, prenatal screening and diagnosis, and indeterminate diagnoses in newborn-screened infants and symptomatic adults., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
49. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
- Author
-
Sontag MK, Lee R, Wright D, Freedenberg D, and Sagel SD
- Subjects
- Algorithms, Biomarkers blood, Cystic Fibrosis blood, Cystic Fibrosis enzymology, Cystic Fibrosis genetics, Dried Blood Spot Testing, Female, Follow-Up Studies, Genetic Markers, Humans, Immunologic Tests, Infant, Newborn, Male, Mutation, Predictive Value of Tests, Retrospective Studies, Sensitivity and Specificity, United States, Cystic Fibrosis diagnosis, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Genetic Testing, Neonatal Screening methods, Trypsinogen blood
- Abstract
Objective: To evaluate the performance of a new cystic fibrosis (CF) newborn screening algorithm, comprised of immunoreactive trypsinogen (IRT) in first (24-48 hours of life) and second (7-14 days of life) dried blood spot plus DNA on second dried blood spot, over existing algorithms., Study Design: A retrospective review of the IRT/IRT/DNA algorithm implemented in Colorado, Wyoming, and Texas., Results: A total of 1 520 079 newborns were screened, 32 557 (2.1%) had abnormal first IRT; 8794 (0.54%) on second. Furthermore, 14 653 mutation analyses were performed; 1391 newborns were referred for diagnostic testing; 274 newborns were diagnosed; and 201/274 (73%) of newborns had 2 mutations on the newborn screening CFTR panel. Sensitivity was 96.2%, compared with sensitivity of 76.1% observed with IRT/IRT (105 ng/mL cut-offs, P < .0001). The ratio of newborns with CF to heterozygote carriers was 1:2.5, and newborns with CF to newborns with CFTR-related metabolic syndrome was 10.8:1. The overall positive predictive value was 20%. The median age of diagnosis was 28, 30, and 39.5 days in the 3 states., Conclusions: IRT/IRT/DNA is more sensitive than IRT/IRT because of lower cut-offs (∼97 percentile or 60 ng/mL); higher cut-offs in IRT/IRT programs (>99 percentile, 105 ng/mL) would not achieve sufficient sensitivity. Carrier identification and identification of newborns with CFTR-related metabolic syndrome is less common in IRT/IRT/DNA compared with IRT/DNA. The time to diagnosis is nominally longer, but diagnosis can be achieved in the neonatal period and opportunities to further improve timeliness have been enacted. IRT/IRT/DNA algorithm should be considered by programs with 2 routine screens., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
50. Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.
- Author
-
Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK, Naehrlich L, Castellani C, Strug LJ, Rommens JM, and Gonska T
- Subjects
- Adolescent, Adult, Alleles, Canada epidemiology, Child, Cystic Fibrosis diagnosis, Cystic Fibrosis epidemiology, Female, Genetic Association Studies, Genotype, Humans, Ileus diagnosis, Male, Phenotype, Prevalence, Registries, Respiratory Function Tests, Severity of Illness Index, Young Adult, Cystic Fibrosis complications, Cystic Fibrosis genetics, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Ileus epidemiology, Ileus etiology, Meconium, Mutation
- Abstract
Rationale: Meconium ileus (MI) is a perinatal complication in cystic fibrosis (CF), which is only minimally influenced by environmental factors. We derived and examined MI prevalence (MIP) scores to assess CFTR phenotype-phenotype correlation for severe mutations., Method: MIP scores were established using a Canadian CF population (n = 2,492) as estimates of the proportion of patients with MI among all patients carrying the same CFTR mutation, focusing on patients with p.F508del as the second allele. Comparisons were made to the registries from the US CF Foundation (n = 43,432), Italy (Veneto/Trentino/Alto Adige regions) (n = 1,788), and Germany (n = 3,596)., Results: The prevalence of MI varied among the different registries (13-21%). MI was predominantly prevalent in patients with pancreatic insufficiency carrying "severe" CFTR mutations. In this severe spectrum MIP scores further distinguished between mutation types, for example, G542X (0.31) with a high, F508del (0.22) with a moderate, and G551D (0.08) with a low MIP score. Higher MIP scores were associated with more severe clinical phenotypes, such as a lower forced expiratory volume in 1 second (P = 0.01) and body mass index z score (P = 0.04)., Conclusions: MIP scores can be used to rank CFTR mutations according to their clinical severity and provide a means to expand delineation of CF phenotypes.Genet Med 18 4, 333-340.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.